A comparison of computational models with and without genotyping for prediction of response to second-line HIV therapy

HIV Medicine

Volumn 15, Issue 7, 2014, Pages 442-448

  Revell, Andrew D ^a   Boyd, M A ^b   Wang, D ^a   Emery, S ^b   Gazzard, B ^c   Reiss, P ^d,e   van Sighem, Al ^e   Montaner, J S ^f   Lane, H C ^g   Larder, B A ^a  

^a HIV Resistance Response Database Initiative (RDI)   (United Kingdom)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e STICHTING HIV MONITORING   (Netherlands)

^f BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Antiretroviral; Computational model; Genotype; HIV; Response prediction

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACCURACY; ADULT; AREA UNDER THE CURVE; ARTICLE; CD4 LYMPHOCYTE COUNT; COMPARATIVE STUDY; CORRELATION ANALYSIS; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; TREATMENT RESPONSE; VIRUS LOAD; BIOLOGICAL MODEL; COMPUTER SIMULATION; DRUG EFFECTS; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS; MIDDLE AGED; PREDICTIVE VALUE; VIROLOGY;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COMPUTER SIMULATION; FEMALE; GENOTYPE; HIV; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL LOAD;

EID: 84904055237     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12156     Document Type: Article

References (11)

1. Thompson MA, Aberg JA, Hoy JF etal. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the international AIDS society-USA panel. JAMA 2012; 308: 387-402.
2. Smith DM, Schooley RT. Running with scissors: using antiretroviral therapy without monitoring viral load. Clin Infect Dis 2008; 46: 1598-1600.
3. World Health Organisation. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for A Public Health Approach. Geneva, WHO, 2013.
4. Second-Line Study Group. Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study. Lancet 2013; 381: 2091-2099.
5. Revell AD, Wang D, Boyd MA etal. The development of an expert system to predict virological response to HIV therapy as part of an online treatment support tool. AIDS 2011; 25: 1855-1863.
6. Larder BA, Revell AD, Mican J etal. Clinical evaluation of the potential utility of computational modeling as an HIV treatment selection tool by physicians with considerable HIV experience. AIDS Patient Care STDs 2011; 25: 29-36.
7. Revell AD, Wang D, Wood R etal. Computational models can predict response to HIV therapy without a genotype and may reduce treatment failure in different resource-limited settings. J Antimicrob Chemother 2013; 68: 1406-1414.
8. Revell AD, Wang D, Wood R etal. An update to the HIV-TRePS system: the development of new computational models that do not require a genotype to predict HIV treatment outcomes. J Antimicrob Chemother 2014; 69: 1104-1110.
9. Revell AD, Wang D, DeWolf F etal. The development of new computational models for the HIV-TRePS online treatment selection tool. XIX International AIDS Conference. Washington DC, USA, July 2012 [Abstract TUPE091].
10. Revell AD, Alvarez-Uria G, Wang D etal. Potential impact of a free online HIV treatment response prediction system for reducing virological failures and drug costs after antiretroviral therapy failure in a resource-limited setting. BioMed Res Int 2013; doi 10.1155/2013/579741 [Epub ahead of print].
11. Katzenstein D. HIV RNA and Genotype in resource limited settings. Can we do better? Clin Infect Dis 2013; 58: 110-112.